Sciencejump web allows a pool of scientists to exchange information, know-how, experience, and connections that can only be exchanged via peer-to-peer interactions. It’s potential to change, how science is done results from the collective intelligence that is updated with every post, comment and new member.

Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The unique mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). Our preclinical results show rapid depletion of C3 without any observed significant adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin.A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings.We have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). We have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH).Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the unique and potent activity of HC3-1496. We intend to initiate human clinical trials in selected indications within 18 months.

Co-founder InCode BioPharmaceutics, inc.InCode is developing a new class of pharmaceutical for the regulation of the complement cascade. These recombinant proteins will offer new therapies for autoimmune and inflammatory diseases.

Nutraceutix, inc. provided contract pharmaceutical, OTC and health product development as well as contract manufacturing and fermentation services. The company grew to 100 employees. The company, was re-named Scolr Pharma and focused exclusively on technology for the Controlled Delivery of Pharmaceuticals. Scolr has developed an extensive pipeline of controlled delivery heart medications (Diltiazem, Nefedipine, Verapamil), and medications for Diabetes, Pain and Asthma. Scolr is a public company.

BTL developed, produced proprietary animal health products for large scale cattle, poultry and swine production. Many of these products have been in use for over 15 years.

Ecova applied genetic engineering and biotechnology to the development of proprietary bacteria for the remediation of hazardous waste. The company successfully demonstrated its technology on 17 superfund sites. The company had numerous contracts with many fortune 500 companies.